TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination
- 8 September 2021
- journal article
- research article
- Published by Springer Nature in Nature Cell Biology
- Vol. 23 (9) , 978-991
Abstract
The extracellular-signal-regulated kinases ERK1 and ERK2 (hereafter ERK1/2) represent the foremost mitogenic pathway in mammalian cells, and their dysregulation drives tumorigenesis and confers therapeutic resistance. ERK1/2 are known to be activated by MAPK/ERK kinase (MEK)-mediated phosphorylation. Here, we show that ERK1/2 are also modified by lysine-63 (K63)-linked polyubiquitin chains. We identify the tripartite motif–containing protein TRIM15 as a ubiquitin ligase and the tumour suppressor CYLD as a deubiquitinase of ERK1/2. TRIM15 and CYLD regulate ERK ubiquitination at defined lysine residues through mutually exclusive interactions as well as opposing activities. K63-linked polyubiquitination enhances ERK interaction with and activation by MEK. Downregulation of TRIM15 inhibits the growth of both drug-responsive and drug-resistant melanomas. Moreover, high TRIM15 expression and low CYLD expression are associated with poor prognosis of patients with melanoma. These findings define a role of K63-linked polyubiquitination in the ERK signalling pathway and suggest a potential target for cancer therapy.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (R01CA184867, R01CA235760, R01CA243520)
This publication has 65 references indexed in Scilit:
- The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and TumorigenesisCell, 2012
- Protein kinases: evolution of dynamic regulatory proteinsTrends in Biochemical Sciences, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Rewired ERK-JNK Signaling Pathways in MelanomaCancer Cell, 2007
- TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activityNature, 2007
- Mutations of the BRAF gene in human cancerNature, 2002
- Activation of the IκB Kinase Complex by TRAF6 Requires a Dimeric Ubiquitin-Conjugating Enzyme Complex and a Unique Polyubiquitin ChainCell, 2000